Abstract
Though depression is prevalent in patients with cerebrovascular dysfunction, screening for symptoms is not routine and is often limited via subjective patient-reported surveys. Using smartphone sensors, we sought to evaluate the performance of objective behavior measures and self-report surveys at predicting depression severity in patients with cerebrovascular syndromes. Among enrolled participants (n = 54), 35 patients with ischemic stroke or transient ischemic attack symptoms were monitored in real-world settings using the Beiwe app for 8 or more weeks with adequate compliance. Depression symptoms were tracked via weekly Patient Health Questionnaire-8 (PHQ-8) surveys, monthly personnel-administered Montgomery-Asberg Depression Rating Scale (MADRS) assessments, and passive smartphone sensors. Across weeks, several passive measures were significantly associated with PHQ-8 scores. Personnel-assessed depression severity moderately correlated with self-reported scores. To estimate MADRS, we applied linear mixed models using passive data and PHQ-8 scores. Using antecedent PHQ-8 scores and demographic data, average root-mean-squared error (RMSE) for depression severity prediction across models was 1.54 with accelerometer data, 1.40 also including global position system (GPS) data, and 1.33 also including PHQ-8 open survey duration. Though future research should validate this decentralized approach in a larger cohort, real-world monitoring with active and passive data may triage cerebrovascular patients for efficient depression screening and provide novel mobility and response time outcome measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by Mayo Clinic. SJZ was supported by a predoctoral fellowship in value assessment from the PhRMA Foundation, a National Center for Advancing Translational Sciences TL1 training grant (5TL1TR002380-05), a P.E.O. Scholar award, and a Kosciusko Foundation graduate scholar award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Mayo Clinic gave ethical approval for this work (22-009345).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.